Literature DB >> 2123239

Lack of impact of early antibiotic therapy for streptococcal pharyngitis on recurrence rates.

M A Gerber1, M F Randolph, K K DeMeo, E L Kaplan.   

Abstract

To determine whether recurrence rates for group A beta-hemolytic streptococcal (GABHS) pharyngitis are related to the time of initiation of antibiotic therapy, we randomly assigned 113 patients with GABHS pharyngitis either to a group that began a 10-day course of penicillin V at the time of diagnosis or to a group that began the same antibiotic regimen after a dealy of 48 hours. Follow-up throat culture specimens were obtained 4 days, 2 months, and 4 months after the completion of antibiotic therapy, as well as during any interim episodes of acute pharyngitis. Serotyping of all GABHS isolates was performed to distinguish between recurrences with homologous serotypes and new acquisitions with heterologous serotypes. There was no significant difference between the two treatment groups in age, gender, duration of illness before enrollment in the study, initial clinical presentation, or compliance. Of the 50 patients in the immediate-treatment group, 6 (12%) had homologous serotypes of GABHS isolated on one of the follow-up throat cultures. Of the 63 patients in the delayed-treatment group, 9 (14%) had homologous serotypes of GABHS isolated on one of the follow-up throat cultures. These data indicate that a 48-hour delay in the initiation of penicillin therapy for GABHS pharyngitis does not reduce the recurrence rate.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2123239     DOI: 10.1016/s0022-3476(05)80121-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  18 in total

1.  Antibiotic prescribing and admissions with major suppurative complications of respiratory tract infections: a data linkage study.

Authors:  Paul Little; Louise Watson; Stephen Morgan; Ian Williamson
Journal:  Br J Gen Pract       Date:  2002-03       Impact factor: 5.386

2.  Streptococcal pharyngitis: is penicillin still the drug of choice?

Authors:  K R Rajesh; R C Gordon
Journal:  Indian J Pediatr       Date:  1996 Jul-Aug       Impact factor: 1.967

3.  Penicillin for acute sore throat in children: randomised, double blind trial. Commentary: More valid criteria may be needed.

Authors:  Paul Little
Journal:  BMJ       Date:  2003-12-06

Review 4.  Pharmacoeconomics of antibacterial treatment.

Authors:  P G Davey; M M Malek; S E Parker
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

5.  Do patients with sore throat benefit from penicillin? A randomized double-blind placebo-controlled clinical trial with penicillin V in general practice.

Authors:  C F Dagnelie; Y van der Graaf; R A De Melker
Journal:  Br J Gen Pract       Date:  1996-10       Impact factor: 5.386

6.  Streptococcus pyogenes pharyngitis: characterization of strains by multilocus enzyme genotype, M and T protein serotype, and pyrogenic exotoxin gene probing.

Authors:  J M Musser; B M Gray; P M Schlievert; M E Pichichero
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

Review 7.  Rapid diagnosis of pharyngitis caused by group A streptococci.

Authors:  Michael A Gerber; Stanford T Shulman
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

8.  Evaluation of potential factors contributing to microbiological treatment failure in Streptococcus pyogenes pharyngitis.

Authors:  S M Kuhn; J Preiksaitis; G J Tyrrel; T Jadavji; D Church; H D Davies
Journal:  Can J Infect Dis       Date:  2001-01

Review 9.  Addressing the burden of group A streptococcal disease in India.

Authors:  Anita Shet; Edward Kaplan
Journal:  Indian J Pediatr       Date:  2004-01       Impact factor: 1.967

10.  Carriage of Streptococcus pyogenes among infants and toddlers attending day-care facilities in closed communities in southern Israel.

Authors:  P Yagupsky; D Landau; A Beck; R Dagan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-01       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.